secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001104659-25-029580
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics enters warrant inducement deal for ~$1.64M gross proceeds
--------------------------------------------------------------------------------

- Holder to exercise existing warrants for 1,381,383 shares; new warrants at 200% of exercised shares.
- New warrants have $1.19 exercise price, exercisable after stockholder approval, 5-year term.
- Gross proceeds ~$1.64M; net proceeds for working capital and general corporate purposes.
- Maxim Group acting as inducement agent with 6% cash fee and $12,500 expenses.
- Company must seek stockholder approval within 90 days; resale registration statement to be filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925029580/0001104659-25-029580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925029580/tm2510890d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer